BackAmbrx Biopharma Overview

Ambrx Biopharma Current Cash

Track Ambrx Biopharma's current cash ($230M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$225.26M
↑ 305.07% YoYΔ $169.65M vs prior year quarter

Peer average

Loading

Ambrx Biopharma Current Cash History

Loading

Ambrx Biopharma vs. peers: Current Cash Comparison

Loading

Ambrx Biopharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ambrx Biopharma (AMAM) FAQ

The latest current cash for AMAM is $230M as of September 2023. That compares with $56M in the prior-year period — up 305.1% year over year. Investors often review this figure alongside Ambrx Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMAM's current cash moved from $56M to $230M — a 305.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ambrx Biopharma's operating scale or balance-sheet position.

A current cash figure of $230M for AMAM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AMAM's current cash ($230M), review year-over-year change from $56M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Ambrx Biopharma's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.